<DOC>
	<DOCNO>NCT00207675</DOCNO>
	<brief_summary>A study safety efficacy infliximab ( Remicade ) pediatric patient moderate severe Crohn 's Disease</brief_summary>
	<brief_title>A Study Safety Efficacy Infliximab ( Remicade ) Pediatric Patients With Crohn 's Disease</brief_title>
	<detailed_description>This medical research study evaluate safety effectiveness antibody call infliximab ( Remicade ) treatment child Crohn 's disease . In study , subject receive multiple dos infliximab 62 week . The goal study ensure medication safe effective child give extended period time . All subject receive induction regimen 5 mg/kg infliximab Weeks 0 , 2 , 6 . Subjects receive either 5 10 mg/kg infliximab either every 8 12 week 46 week follow open label extension three additional year .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Between age 6 17 year Have Crohn 's disease diagnose least 3 month prior screen , gastritis , duodenitis , colitis , ileitis , ileocolitis , previously confirm endoscopy biopsy Have active Crohn 's disease despite adequate current treatment immunomodulator ( ie , AZA , 6MP , MTX ) . Disease complication surgery might indicate Surgery bowel diversion placement stoma within 3 month prior screen Positive stool examination enteric pathogen include Giardia lamblia , Clostridium difficile , Shigella specie , Salmonella specie .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>pediatric Crohn 's Disease</keyword>
</DOC>